Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 versus physician-selected chemotherapy in previously treated recurrent or metastatic nasopharyngeal carcinoma
ChiCTR2600134160Phase 3Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Objective response rate assessed by blinded independent central review, Overall survival and 1 more. Started Sep 2023; status: completed.
02
Drugs
izalontamab brengitecan
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600134160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134160.